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Posttranslational modifications of core histones are central to the regulation of gene expression. Histone
deacetylases (HDACs) repress transcription by deacetylating histones, and class I HDACs have a crucial role
in mouse, Xenopus laevis, zebra fish, and Caenorhabditis elegans development. The role of individual class I
HDACs in tumor cell proliferation was investigated using RNA interference-mediated protein knockdown. We
show here that in the absence of HDAC1 cells can arrest either at the G1 phase of the cell cycle or at the G2/M
transition, resulting in the loss of mitotic cells, cell growth inhibition, and an increase in the percentage of
apoptotic cells. On the contrary, HDAC2 knockdown showed no effect on cell proliferation unless we concur-
rently knocked down HDAC1. Using gene expression profiling analysis, we found that inactivation of HDAC1
affected the transcription of specific target genes involved in proliferation and apoptosis. Furthermore, HDAC2
downregulation did not cause significant changes compared to control cells, while inactivation of HDAC1,
HDAC1 plus HDAC2, or HDAC3 resulted in more distinct clusters. Loss of these HDACs might impair cell
cycle progression by affecting not only the transcription of specific target genes but also other biological
processes. Our data support the idea that a drug targeting specific HDACs could be highly beneficial in the
treatment of cancer.
In eukaryotic cells, the balance between acetylation and
deacetylation is critical for gene transcription and for the func-
tions of different cellular proteins. Histone acetylation is regu-
lated by both histone acetyltransferases and histone deacetylases
(HDACs), which are conserved from yeast (Saccharomyces cer-
evisiae) to humans. Mammalian HDACs have been grouped
into three classes according to their homology to yeast pro-
teins. The class I enzymes HDAC1 and HDAC2 are ubiqui-
tously expressed and seem to be involved in more-general
cellular processes. According to its sequence, HDAC3 also
belongs to the class I family, but since it can interact with both
class I and class II enzymes it could represent the functional
link between the two families (11). Class II enzymes have
tissue-specific functions, and class III enzymes are NAD de-
pendent and are involved in the control of the life span of
certain organisms (15, 16, 33). Recently, class IV, which in-
cludes HDAC11-related enzymes, has been added (12, 15).
Because of the connection between transcriptional repression
and HDAC recruitment, HDAC inhibitors may reverse si-
lenced genes (reviewed in reference 30).
HDAC inhibitors are a new class of drugs with anticancer
potential. They have been shown to induce apoptosis effec-
tively in cancer cells and are currently in clinical trials for a
variety of cancers (4, 40). One example includes the HDAC
inhibitor suberoylanilide hydroxamic acid, which recently has
been shown to induce polyploidy in human cancer cell lines
(55). As we learn more about HDACs and the biological pro-
cesses they regulate, a strong idea that the identities of the
relevant target deacetylases need to be determined to aid in
the development of HDAC inhibitors as anticancer agents is
emerging. One clear example is the demonstration of HDAC2
induction upon loss of the adenomatosis polyposis coli tumor
suppressor in colorectal tumorigenesis, providing a reason for
treating certain carcinomas with HDAC inhibitors (58). Inter-
estingly, it has been demonstrated previously that the HDAC
inhibitor valproic acid selectively induces polyubiquitination
and proteasomal degradation of HDAC2 (35). Lately, HDAC3
was found to be required for normal mitotic progression and
maximal phosphorylation of histone 3 (H3) on Ser 10 (S10)
in mitosis (38). Phosphorylation of H3 on S10 is a well-
characterized and evolutionary conserved mitotic event (6,
17, 22, 23, 45).
Recent experiments with small interfering RNA (siRNA)
implicated HDAC1 and HDAC3 in the regulation of prolifer-
ation and survival of cancer cells (13). In particular, the idea
that HDAC1 can also be a potential target for therapeutic
intervention in certain cancers stems from a series of studies.
HDAC1 has been shown to inhibit estrogen receptor alpha
protein expression and transcriptional activity, suggesting that
it can modulate breast cancer progression (32). Overexpres-
sion of HDAC1 at mRNA and protein levels was reported for
human gastric and prostate tumors (5, 18, 34, 44), whereas
overexpression of HDAC3 is seen with colon tumors (54).
Furthermore, published data indicate a role of mouse HDAC1
in the regulation of proliferation and development. For in-
stance, the expression of HDAC1 is induced upon growth
* Corresponding author. Mailing address: European Institute of On-
cology, Department of Experimental Oncology, Via Ripamonti 435,
20141 Milan, Italy. Phone: 39-02-57489835. Fax: 39-02-57489851. E-mail:
susanna.chiocca@ifom-ieo-campus.it.
 Published ahead of print on 30 April 2007.
4784
 at European School of M
olecular M








factor activation of mouse T cells and fibroblasts (3, 19) and
HDAC1 levels were found to be elevated in highly proliferative
tissues, embryonic stem (ES) cells, and several transformed
cell lines (3, 37), suggesting a link between HDAC1 function
and proliferation. In accordance with this idea, disruption of
the HDAC1 gene resulted in reduced proliferation of mouse
embryos and ES cells (37), whereas overexpression of HDAC1
led to impaired cell proliferation of murine fibroblasts (3).
Taken together, these results suggest that class I HDACs are
crucial in controlling the proliferation state of mammalian
cells.
HDAC1 and HDAC2 often heterodimerize and are gener-
ally found in large multiprotein complexes: the Sin3, NuRD,
and CoREST complexes (16). Numerous transcription factors,
including regulators of cell cycle, differentiation, and develop-
ment, have been shown to associate directly with HDAC1 and
HDAC2 or with HDAC1/HDAC2 complexes, thereby mediat-
ing the repression of specific target genes (1, 7, 42). Further-
more, the loss of Sds3, a component of the Sin3/HDAC1/
HDAC2 complex and a putative recruiting factor, led to cell
death due to missegregation of chromosomes during mitosis
(8). Therefore, both HDAC1- and HDAC1/HDAC2-mediated
chromatin modifications seem to be important for cell cycle
control and development. In light of this evidence, we con-
ducted a study to analyze the effect of depleting class I deacety-
lases in human tumor cells by RNA interference (RNAi). We
show here that by ablating either HDAC1 or HDAC3 protein
expression there is an inhibition of tumor cell proliferation.
Clearly, HDAC1 knockdown abolishes the ability of tumor
cells to proceed through mitosis. On the contrary, HDAC2
knockdown shows no effect, unless we concurrently knock
down both HDAC1 and HDAC2. In addition, we also con-
ducted an analysis of the changes in gene expression in U2OS
cells in response to knockdown of deacetylases and demon-
strated that a large number of HDAC target genes are involved
in proliferation and apoptosis.
The overall evidence therefore points to the idea that each
individual class I HDAC plays a different role in regulating
genes involved in various biological processes.
MATERIALS AND METHODS
Cell culture. U2OS and MCF7 cell lines were grown in Dulbecco’s modified
Eagle’s medium (Cambrex) supplemented with 10% fetal bovine serum (Cam-
brex), antibiotics, and 2 mM L-glutamine (Cambrex). The MCF10A cell line was
maintained in F12-Dulbecco’s modified Eagle’s medium (1:1) supplemented
with 5% horse serum, 20 ng/ml epidermal growth factor, 0.5 g/ml hydrocorti-
sone, 50 ng/ml cholera toxin, 10 g/ml insulin, and antibiotics. All cell lines were
cultured in a humidified 37°C incubator with 5% CO2.
Transfection of cells with siRNA, electrophoresis, and Western blotting.
siRNAs were ordered from MWG BIOTECH and prepared according to the
manufacturer’s instructions (stock concentration of 20 M in molecular-biology-
grade water). Oligofectamine was used for all siRNA transfections (Invitrogen,
San Diego, CA). The following siRNA sequences were used: 5-CGUACGCG
GAAUACUUCGATT-3 for siRNA LUC (control), 5-CAGCGACUGUUUG
AGAACCTT-3 and 5-CUAAUGAGCUUCCAUACAATT-3 for siRNA
HDAC1, 5-UCCGUAAUGUUGCUCGAUGTT-3 for siRNA HDAC2, and
5-GAUGCUGAACCAUGCACCUTT-3 for siRNA HDAC3.
Oligofectamine reagent was diluted and used according to the manufacturer’s
instructions. The amount of siRNA used was optimized and fixed for each
knockdown experiment. A second cycle of siRNA transfection was performed
24 h later. Cells were harvested 72 h after the first cycle of transfection and stored
at 80°C until lysis in urea buffer (8 M urea, 0.1 M NaH2PO4, 0.01 M Tris,
pH 8).
After Western blotting, primary antibodies anti-HDAC1 (monoclonal mouse
antibody; Upstate), anti-HDAC3 (ab 7030; Abcam), and anti-caspase-3 (H-277;
Santa Cruz Biotechnology) were incubated with membrane overnight at 4°C;
anti-HDAC2 (ab 7029; Abcam), anti-p21 (a kind gift from K. Helin’s lab),
anti-acetylated H3/H4 (in-house antibody), antitubulin (DM1A; Sigma), and
anti-H3 (ab 1791; Abcam) were incubated for 2 h at room temperature. Proteins
were visualized by chemiluminescence with ECL Western blotting detection
reagents (Amersham Biosciences).
Growth curve. To determine the effects of siRNA knockdown on cell prolif-
eration, 24 h after transfection, cells were collected by trypsinization, counted by
use of a hemacytometer with trypan blue dye, and plated at 3,000 viable cells/well
for U2OS and MCF7 or 2,000 viable cells/well for MCF10A into a 96-well tissue
culture dish in a final volume of 200 l. Every 24 h, a 96-well tissue culture dish
was stained with crystal violet solution and left to dry. Then, crystal violet
incorporated in the cellular membrane was solubilized with a solution of 10%
acetic acid–phosphate-buffered saline (PBS) and the absorbance at 595 nm was
measured with an MRX microplate reader (Dynatech). We calculated the in-
crease (n-fold) of the absorbance as the ratio of absorbance at time i/absorbance
at time zero (where time i is 48, 72, or 96 h after siRNA transfection and time
zero is 48 h after transfection). Each experimental point is the average of three
independent experiments, with the respective standard deviation.
Colony formation assay. Twenty-four hours after transfection, cells were col-
lected by trypsinization, counted by use of a hemacytometer with trypan blue dye,
and plated at 3,000 viable cells/well for U2OS and MCF7 or 2,000 viable cells/
well for MCF10A into a six-well tissue culture dish. Six days after plating, cells
were stained with crystal violet solution (1% crystal violet, 35% ethanol) and
colonies were counted. We calculated the relative CFU as follows: number of
colonies of each sample/number of colonies of the control. The average relative
CFU of three plates was calculated, with the respective standard deviation.
Fluorescence-activated cell sorter (FACS) analysis of cell cycle. To detect
HDAC1, phosphorylated S10 at H3 (H3-P), and DNA or HDAC1, cyclin A, and
DNA, 72 h after the first cycle of transfection, both attached cells and superna-
tant were collected and resuspended at 106 cells/ml in 1% formaldehyde for 15
min. After PBS washing, the pellet was resuspended in ice-cold 70% ethanol and
stored at 4°C. For immunodetection, cells were washed twice in PBS and per-
meabilized in 0.1% Triton X-100 in PBS for 10 min. After being blocked in 5%
normal goat serum for 20 min, cells were incubated with anti-HDAC1 mouse
monoclonal antibody (Upstate), 1:250, and anti-H3-P rabbit polyclonal antibody
(Upstate) or anti-cyclin A (Pharmingen), 1:100, in PBS plus 1% bovine serum
albumin for 2 h at room temperature. Cells were rinsed in PBS and incubated for
1 h with Cy5-conjugated goat anti-mouse (1:50; Jackson Immunoresearch) and
fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit antibodies. Cells
were washed again and resuspended in 1 ml of a solution containing 2.5 g/ml
propidium iodide (PI) (Sigma) in PBS and 250 g/ml RNase in PBS and incu-
bated overnight at 4°C before acquisition.
Samples were acquired on a FACSCalibur (Becton Dickinson) flow cytometer.
At least 10,000 events were acquired. Analysis was performed using CellQuest
3.3 (Becton Dickinson).
FACS analysis for activation of caspase-3. For active caspase-3 analysis, 96 h
after the first cycle of transfection, both attached cells and supernatant were
collected, fixed in 1% formaldehyde in PBS and then in 70% cold ethanol, and
permeabilized in 0.1% Triton X-100 for 10 min. Prior to incubation with anti-
caspase-3 polyclonal antibody (9661L; Cell Signaling), cells were incubated for
30 min with 10% goat serum in PBS. After being washed, cells were incubated
with anti-rabbit FITC antibody (Sigma) for 1 h at room temperature (light
protected). The labeled cells were stained overnight at 4°C in 2.5 g/ml PI
and RNase 250 g/ml in PBS. The cellular suspension was passed through a
FACSCalibur (Becton Dickinson) flow cytometer. At least 10,000 events were
acquired, and analysis was performed using CellQuest 3.3 (Becton Dickinson)
and ModFit LT 3.1 software.
Cell synchronization. Twenty-four hours after the first cycle of siRNA trans-
fection (see above), cells were synchronized in the G1/S transition by treatment
with 2 mM thymidine for 14 h, released for 8 h, and then treated again with
thymidine for 14 h. After two washes with PBS, cells were cultured in fresh
medium or in medium with 0.1 g/ml nocodazole for different times (as indicated
in each experiment) and harvested. Cells were synchronized in prometaphase by
treatment with 0.1 g/ml nocodazole for 16 h and then released from the
drug-induced cell cycle block by being washed three times with PBS.
Time-lapse microscopy. Time-lapse microscopy was performed by use of a Cell
R imaging station for live-cell microscopy (Olympus) mounted on an IX81
inverted microscope (Olympus) equipped with an incubation chamber (Evotec).
The system includes a Hamamatsu ORCA-ER charge-coupled-device camera
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for image acquisition. A movie montage was performed using ImageJ image
analysis software (W. Rasband, National Institutes of Health, Bethesda, MD).
Statistical immunofluorescence. Forty-eight hours after siRNA transfection,
cells were plated on four-chamber slides pretreated with 15 g/ml poly(D)lysine
(Sigma) and treated with 0.1 g/ml nocodazole for 16 h to enrich the mitotic
population. Slides were fixed in 4% paraformaldehyde–1 PIPES [piperazine-
N,N-bis(2-ethanesulfonic acid)] for 10 min, permeabilized with 0.1% Triton
X-100 and 0.2% bovine serum albumin in PBS, and processed using standard
protocols. The primary antibodies used were anti-HDAC1 monoclonal (Upstate)
at 1:250 and anti-H3-P rabbit polyclonal (Upstate) at 1:100, and the conjugated
secondary antibodies were Cy3-conjugated goat anti-mouse (Jackson Laborato-
ries) and FITC-conjugated goat anti-rabbit (Sigma). DAPI (4,6-diamino-2-
phenylindole) (Sigma) was used for nuclear counterstaining. Fluorescence mi-
croscopy images were acquired using a BX61 (Olympus) motorized fluorescence
microscope. Acquired images were visualized using a browser developed with the
ImageJ macro language. After acquisition of DAPI, Cy3, and FITC channels,
DAPI staining was employed to identify cell nuclei and to build a mask for
successive calculations. The mean nuclear levels of DAPI, HDAC1, and H3-P
were stored in the memory to allow later statistical analysis. HDAC1 fluores-
cence distribution was evaluated in control- and HDAC1-interfered cells in order
to establish an arbitrary threshold used to discriminate HDAC1-positive (gate II)
and HDAC1-negative (gate I) cells. H3-P fluorescence distribution was evalu-
ated in gate I and gate II to fix a value above which cells were H3-P positive and
below which they were negative. We evaluated for both gate I and gate II the
percentages of double positive cells.
Extraction of RNA and reverse transcription-PCR. For validation of the mi-
croarray results, we employed independent RNA preparations of the samples
described above. Total RNA was isolated by using a QIAGEN RNeasy Protect
mini kit as described by the manufacturer. cDNA was generated by reverse
transcription-PCR with PE Applied Biosystem TaqMan reverse transcription
reagents. Relative levels of specific mRNA were determined with a 5 nuclease
assay (TaqMan) chemistry system. All PCRs were performed with an ABI
7900HT sequence detection system. The GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) gene was used as a control gene for normalization.
Microarray analysis. Biotin-labeled cRNA targets were obtained from 5 g of
total RNA derived from samples as described above. cDNA synthesis was per-
formed with a Gibco SuperScript custom cDNA synthesis kit, and biotin-labeled
antisense RNA was transcribed using an in vitro transcription system (Ambion,
Inc., Austin, TX) including Bio-11-UTP and Bio-11-CTP in the reaction (NEN
Life Sciences, Boston, MA). GeneChip hybridization, washing, staining, and
FIG. 1. siRNA-mediated knockdown of HDAC1, HDAC2, and HDAC3 in U2OS, MCF7, and MCF10A cells. The loss of both HDAC1 and
HDAC2 produced a hyperacetylation of histones H3 and H4. (A to C) Relative (rel.) expression levels of the indicated mRNAs were determined
by real-time PCR, as described in Materials and Methods. Averages of three independent experiments are shown, and standard deviations are
indicated by the error bars. (D to F) Western blots of U2OS whole-cell extracts after transfection of siRNA HDAC1, HDAC2, HDAC3, and
HDAC1 plus HDAC2. Cells were transfected and processed as described in Materials and Methods, and 30 g was loaded per lane. As a control
(CTRL), we used transfection of antiluciferase siRNA.
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scanning were performed according to Affymetrix protocols (Santa Clara, CA).
Two copies of the HG-U133Plus GeneChip were hybridized with each target.
Full details of microarray methods are described in the supplementary data
posted at http://bio.ifom-ieo-campus.it/supplementary/MCB49407/.
RESULTS
siRNA-mediated knockdown of HDAC1 to HDAC3. We es-
tablished the methodology for HDAC class I knockdown in
various cell lines: U2OS (an osteosarcoma cell line), MCF7 (a
mammary carcinoma cell line), and MCF10A (an epithelial
mammary gland cell line). As shown in Fig. 1A to F, the
expression levels of these HDACs were efficiently knocked
down by the respective siRNAs. It is interesting to note that
the levels of endogenous HDAC1 and HDAC2 in all three cell
lines increase in opposition to one other (Fig. 1D to F), i.e.,
upon knockdown of one the other one increases at the protein
level. On the other hand, we observed a decrease of both
HDAC1 and HDAC2 upon HDAC3 knockdown, but only at
the protein level. We still do not know the reason for this
result, but preliminary data indicate that it is proteasome de-
pendent. Nevertheless, reduced expression of HDAC1 and
HDAC2 could also be a consequence of the reduced cellular
viability after HDAC3 knockdown (Fig. 2).
The absence of HDAC1 induces p21 expression only in the
U2OS cell line, and the absence of both HDAC1 and HDAC2
increases histone acetylation. One important proliferation-re-
lated function of HDAC1 is to prevent the inappropriate ex-
pression of the cyclin-dependent kinase (CDK) inhibitors p21
and p27 (37). In accordance with this model, the promoters of
the genes for p21 and p27 are hyperacetylated in HDAC1 null
cells (37). In addition, HDAC1 can be recruited to the p21
gene by the transcription factor SP1 (36) and Tbx2 (51) and
p21 is one of the genes upregulated after HDAC inhibitor
treatment (29, 30, 47, 48). Therefore, we analyzed endogenous
p21 protein levels after RNAi treatment. Figure 1D indicates
that p21 levels increase in the absence of either HDAC1 alone
or HDAC1 plus HDAC2 in U2OS cells, in accordance with
HDAC1 null embryo results (37) and with the effect of HDAC
inhibitors (47). Conversely, in both MCF7 and MCF10A, we
did not observe any changes in p21 levels after HDAC1 or
HDAC1 and HDAC2 knockdown (data not shown). Interest-
ingly, only in the absence of both HDAC1 and HDAC2 did
Western blot analysis with modification-specific antibodies re-
veal increased acetylation levels of a subset of histones H3 and
H4 (Fig. 1D to F) in all three cell lines. This result could
indicate that these histones are substrates for both HDACs
and that only the concurrent double knockdown of HDAC1
plus HDAC2 leads to their hyperacetylation. We also noted
that in our system specific knockdown of any HDAC did not
affect basal levels of p53 or its acetylation (data not shown),
reflecting the idea that multiple deacetylases are involved in
regulating p53 acetylation (28, 39, 52).
FIG. 2. Absence of either HDAC1 or HDAC3 causes a defective proliferation. (A to C) Growth curves of U2OS, MCF7, and MCF10A transfected
with HDAC siRNAs. The increase of absorbance at 595 nm is directly correlated with cell proliferation, as described in Materials and Methods. Each
curve represents the average of three independent experiments, and the standard deviation is indicated by the error bars. (D to F) CFU assay of U2OS,
MCF7, and MCF10A cells transfected with HDAC siRNAs. The ratio of the CFU number of each sample/CFU number of the control was calculated.
Each column represents the average of three independent experiments, with the respective standard deviations. CTRL, control.
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siRNA-mediated knockdown of HDAC1 and HDAC3 dimin-
ishes cellular viability and proliferation. It is known that
HDAC inhibitors lead to p21 induction. They also induce cell
cycle arrest in either G1 or G2/M and apoptosis, killing tumor
cells (4, 29, 48). The pathway leading to tumor cell death is still
unknown, but it is very unlikely that a single molecular pathway
will be identified in all cell types for all HDAC inhibitors. We
decided to investigate cellular viability and proliferation of
U2OS, MCF7, and MCF10A cells after HDAC knockdown.
Clearly, the absence of HDAC1, HDAC3, and HDAC1 plus
HDAC2 generated a remarkable defect in proliferation in both
U2OS and MCF7 cell lines (Fig. 2A and B) but had an almost
unnoticeable effect in the MCF10A cell line (Fig. 2C). The lack
of HDAC2 had a much less pronounced effect on all cells (Fig.
2A to C). This is inconsistent with published data but is prob-
ably due to the different cell lines used (24). We then analyzed
the effect of the absence of all three HDACs on the life spans
of all three cell lines. In correlation with the results in Fig. 2A
to C, cells lacking HDAC1, HDAC3, or the combination
HDAC1 plus HDAC2 had a diminished capacity to form col-
onies when plated at a low density (Fig. 2D to F). These data
suggest that both HDAC1 (either alone or in combination with
HDAC2) and HDAC3 have important roles in the prolifera-
tion of tumor cells, in agreement with published data indicating
a relevant role of murine HDAC1 for the regulation of prolif-
eration and development (37). An HDAC3-AKAP95/HA95-
Aurora B pathway regulating mitosis has been demonstrated
recently, explaining the mitotic defect observed after HDAC3
siRNA (38). It is interesting to note that in the cell line
MCF10A, the untransformed counterpart of MCF7, the ab-
sence of all three HDACs had less effect on cellular prolifer-
ation.
HDAC1 knockdown cells have a marked reduction of H3
S10 phosphorylation. H3-P is a mitotic marker. To explore
whether the defect in proliferation of HDAC1 knockdown
cells was due to a mitotic defect, we applied single-cell statis-
tical analysis to both control-interfered and HDAC1-inter-
fered cells by using an anti-HDAC1 antibody and an anti-H3-P
antibody (see Materials and Methods). We analyzed all three
cell lines for mitotic cells in the presence and absence of
HDAC1 (Fig. 3). Figure 3A, B, and C show histograms report-
ing the distributions of HDAC1 levels in control-interfered
populations and HDAC1-interfered populations, as described
in Materials and Methods. As shown in the upper panels, we
were able to discriminate between HDAC1-positive cells (gate
II) and HDAC1-negative cells (gate I). The middle panels
represent the distributions of H3-P levels in the two gates in
order to define the basal level of H3-P-positive cells. In the
lower panels, the correlation between HDAC1 and H3-P levels
in the two gates is represented. Interestingly, knockdown of
HDAC1 led to a clear reduction in the number of H3-P-
positive cells, suggesting that HDAC1 could be important for
proper cell cycle progression. Again, the effect was not as
drastic in the MCF10A cell line (Fig. 3C).
HDAC1 knockdown cells can either arrest in G1 or die
during G2/M transition. We next tested whether HDAC1
knockdown affects cell cycle progression. U2OS cells were
synchronized by a double thymidine block at the G1/S transi-
tion, and cell cycle progression upon removal of thymidine was
monitored by FACS analysis of PI-stained DNA (Fig. 4A, top).
The bottom panel of Fig. 4A represents a biparametric anal-
ysis, done using anti-H3-P and PI staining levels in U2OS cells.
This analysis shows an increase in G1 cells in the absence of
HDAC1 at all time points after thymidine release, accompa-
nied by a lower percentage of mitotic cells.
Next, we released U2OS cells from the double thymidine
block with nocodazole-containing culture medium to enrich
the mitotic population. Biparametric analysis using anti-cyclin
A, a G2 marker, and PI staining (Fig. 4B) showed that by 24 h
control cells were blocked in mitosis as expected but that
HDAC1 knockdown cells were unable to remain in mitosis. In
fact, over time, there was a larger amount of G1/S HDAC1-
negative cells, accompanied by a significant decrease of mitotic
cells and increase of sub-G1 cells.
We next analyzed the proportion of sub-G1 cells after re-
lease from the nocodazole block. As shown in Fig. 4C, we
observed massive apoptosis in HDAC1-negative U2OS cells.
Taken together, these data demonstrate that the proliferative
defect of HDAC1 knockdown cells is due to both partial G1
arrest and cell death either at the G2/M transition or at the
very beginning of mitosis. Alternatively, HDAC1-deficient
cells could become insensitive to nocodazole and grow to be
G1 tetraploids. However, when we followed living cells by time-
lapse microscopy, we observed the inability of HDAC1-nega-
tive cells to condense and enter mitosis, suggesting that these
cells die during G2/M transition (Fig. 4D). Our data confirm
and extend published findings showing that HDAC inhibitors
induce G1 and/or G2/M arrest and/or apoptosis (4).
Induction of apoptosis in HDAC1-deficient U2OS cells. The
observation that there were differences in the numbers of apop-
totic cells after HDAC1 knockdown prompted us to confirm
apoptotic cell death by examining caspase-3 activation, both by
FACS analysis (Fig. 5A) and by Western blot analysis (Fig. 5B)
(see Materials and Methods). Our results indicate that
caspase-3 activation is involved in apoptosis after HDAC1
knockdown.
Comparison of gene expression profiles after depletion of
HDAC1, HDAC2, HDAC3, and HDAC1 plus HDAC2. We then
analyzed the gene expression profiles of U2OS cells upon loss
of HDAC1, HDAC2, HDAC3, or HDAC1 plus HDAC2 by
using HG-U133 Plus Affymetrix oligonucleotide chips, which
explore the expression of approximately 54,000 human tran-
scripts. Results were analyzed using GCOS and further elab-
orated with GenePicker and GeneSpring software (see the
supplementary data posted at http://bio.ifom-ieo-campus.it
/supplementary/MCB49407/) (2, 10). A detailed description of
microarray methods, data analysis and elaboration, and com-
parative results can be found in the supplementary data at the
URL mentioned above.
Ablation of HDAC1, HDAC2, HDAC3, or HDAC1 plus
HDAC2 resulted in the altered expression of 987, 283, 1,317,
or 601 genes, respectively (see supplementary Table 1 posted
at http://bio.ifom-ieo-campus.it/supplementary/MCB49407/).
There is a large degree of overlap between the lists of genes
regulated by siRNA of HDAC1 and those regulated by siRNA
of HDAC1 plus HDAC2. Ablation of HDAC2 results in a mild
phenotype and, compared to the other conditions, is associated
with the deregulated expression of few genes, 86% of which are
also deregulated under one of the two above-mentioned con-
ditions. Only 31% of genes deregulated by HDAC3 siRNA are
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in common with those regulated by siRNA of HDAC1 or
HDAC1 plus HDAC2 (see the supplementary data and sup-
plementary Table 1 posted at the URL mentioned above).
Hierarchical clustering using any of the lists of regulated genes
confirms there is a higher degree of similarity in the gene
expression profiles resulting from ablation of HDAC1, HDAC2,
or HDAC1 plus HDAC2 than in those resulting from ablation
of HDAC3 (Fig. 6).
We next performed a functional classification of genes
deregulated upon knockdown of HDAC1 or HDAC1 plus
HDAC2, according to Gene Ontology Biological Process cat-
egories (for a complete description, see the supplementary
data posted at http://bio.ifom-ieo-campus.it/supplementary
/MCB49407/). To investigate the molecular basis of HDAC1-
mediated growth arrest, we focused our attention on two func-
tional categories: apoptosis and proliferation. We found 36
probe sets (corresponding to 28 nonredundant genes) that
were classified as relevant to apoptosis and 100 probe sets
FIG. 3. Absence of the mitotic marker H3-P in HDAC1-deficient cells. U2OS, MCF-7, and MCF10A cells were analyzed for the presence of
H3-P. (Top) Distribution of the HDAC1 signal over the siRNA-control (CTRL)-transfected and siRNA-HDAC1-transfected populations. The
dashed line represents the arbitrary threshold used to distinguish HDAC1-negative (gate I) from HDAC1-positive (gate II) cells. (Middle)
Distribution of H3-P signals in gate I and gate II. The dashed line represents the arbitrary threshold used to distinguish between positive and
negative H3-P cells. (Bottom) Scatter plot of HDAC1 signal versus H3-P signal. The percentages inside the plot indicate the percentages of double
positive cells.
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FIG. 4. HDAC1-deficient cells arrest in G1 or die during G2/M transition. (A) Asynchronous (As) siRNA-control (CTRL)-transfected (black)
and siRNA-HDAC1-transfected (gray) U2OS cells were blocked in G1/S transition by use of thymidine and then released in fresh medium. (Top)
DNA content was analyzed by FACS analysis of PI-stained cells at different time points after the release in fresh medium. (Bottom) Biparametric
FACS analysis using anti-H3-P and PI staining was performed to calculate the percentages of cells in G1, S, G2, and M phases at each time point.
(B) U2OS control- and HDAC1-interfered cells were blocked in G1/S transition by use of thymidine and then released in medium containing
nocodazole. (Top) DNA content was analyzed by FACS analysis of PI-stained cells at different time points. (Middle) Biparametric FACS analysis
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(corresponding to 72 nonredundant genes) relevant to prolif-
eration. Three genes were present in both categories (F2R,
interleukin-1A [IL1A], and SPP1 genes). Figure 7 shows a
graphical representation of the behavior of these genes in
U2OS cells lacking HDAC1 or HDAC1 plus HDAC2 com-
using anti-cyclin A (CYCA) and PI staining was performed to calculate the percentages of cells in G1/S, G2, and M phases at each time point.
(Bottom) DNA content was analyzed by FACS analysis to evaluate the percentages of sub-G1 cells. (C) U2OS control- and HDAC1-interfered
cells were blocked in G2/M transition by use of nocodazole and then released in fresh medium. (Top) DNA content was analyzed by FACS analysis
on PI-stained cells at different time points. (Bottom) DNA content was analyzed by FACS analysis to evaluate the percentages of sub-G1 cells. (D)
(Top) Percentages of cells in the control- and HDAC1-interfered population able to undergo mitosis at least once in 30 h. (Bottom) Images of
time-lapse experiments with U2OS siRNA-CTRL-transfected and siRNA-HDAC1-transfected cells. Control cells experience normal mitosis
(white arrowheads), while HDAC1 knockdown cells cannot enter in mitosis and they die (yellow and black/white arrowheads).
FIG. 5. HDAC1 knockdown cells undergo apoptosis. (A) Effect of
siRNA HDAC1 on caspase-3 activation by FACS analysis. The bars
represent the percentages of cleaved caspase-3-positive cells in control
(CTRL) and siRNA-HDAC1-transfected U2OS cells after 96 h. The
values correspond to the averages of three independent experiments,
and the error bars indicate the associated standard deviations.
(B) Western blots of U2OS whole-cell extracts after transfection of
control or siRNA HDAC1. Cells were collected 120 h after transfec-
tion, and 50 g of lysates was loaded per lane. As a control, we used
an injection of antiluciferase siRNA. The anti-caspase-3 antibody used
was able to recognize both full-length inactive and cleaved active
forms.
FIG. 6. Gene expression profiles. Supervised hierarchical clustering
(according to Pearson’s correlation) was performed using comparative
expression values of the gene lists indicated above each dendrogram (for
gene lists, see supplementary Table 1 posted at http://bio.ifom-ieo-campus
.it/supplementary/MCB49407/). In all cases, the expression value for the
control cells was used as the baseline (value of 1).
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pared to the behavior in vector-transfected U2OS cells (con-
trol). Clearly, more genes involved in apoptosis were induced
than repressed by RNAi of HDAC1 and/or HDAC1 plus
HDAC2. Multiple proapoptotic genes, including FAS, BCL2-
like 1, and members of the tumor necrosis factor (TNF) family
receptors and ligands (TNFRSF10B, TNFRSF11B, and TNF
RSF12A), were activated. Conversely, approximately equal
numbers of genes involved in cell proliferation were up- and
downregulated. The complete gene lists can be found in sup-
plementary Tables 1 and 2 posted at http://bio.ifom-ieo-campus
.it/supplementary/MCB49407/. To verify changes in gene
expression detected by our microarray analysis, by using
independent RNA preparations of the described experimental
conditions, we performed quantitative real-time PCR analysis
on 19 genes whose expression was altered and which regulate
proliferation and apoptosis (cyclin D2 [CCND2], CCNE2,
CDKN1A [p21], HDAC9, IL6R, IL-9, MYC, ubiquitin-specific
peptidase 16 [USP16], CCNG2, cell division cycle 25C [CDC25C],
CDKN2C, nuclear factor 1A [NF1A], NFIB, septin 6 [SEP6],
transforming growth factor 2 [TGFB2], TNFRSF10B,
FIG. 7. Gene expression profiles and quantitative real-time PCR. (A) Graphic representation of the expression patterns of genes functionally
involved in apoptosis and proliferation regulated by ablation of HDAC1 or HDAC1 plus HDAC2 in U2OS cells. (B) Validation of microarray data
by TaqMan quantitative real-time PCR. The error bars indicate the standard deviations from three independent experiments. CTRL, control.
4792 SENESE ET AL. MOL. CELL. BIOL.
 at European School of M
olecular M








TNFRSF11B, IL-24, and IL1A genes). As shown in Fig. 7, there
was a high correlation between the microarray and the real
-time data for all 19 genes.
We also found some consistency with a recent study identi-
fying several genes within both apoptosis and cell proliferation
pathways regulated by two different HDAC inhibitors over a
16-h culture treatment (46). Although with siRNA experi-
ments it is difficult to discern between early and late events, it
is interesting to note that this study identified that, for exam-
ple, the cell division cycle gene CDC25C and genes encoding
TNF family receptors and ligands were modulated by both
HDAC inhibitors (46). Altogether, these findings support the
idea that HDAC inhibition affects the expression of genes
within pathways that regulate tumor cell growth and survival.
DISCUSSION
HDAC inhibitors induce cell cycle arrest, apoptosis, or dif-
ferentiation in tumor cells, and a number of them have entered
early-phase clinical trials. Based on the phenotype of HDAC1-
deficient embryos and ES cells, HDAC1 was implicated in
proliferation control (37). In this study, we show that HDAC1
has an important role in the proliferation of human tumor cells
and that it influences their capacity to undergo mitosis. Al-
though our study also shows that the absence of HDAC3 has a
drastic effect on cell proliferation, we directed our attention
mostly to the HDAC1 knockdown phenotype. Clearly, our
microarray data indicate that HDAC3 favors more than a few
uniquely expressed genes, compared to HDAC1 and HDAC1
plus HDAC2 (Fig. 6) (also see supplementary Table 1 posted
at http://bio.ifom-ieo-campus.it/supplementary/MCB49407/),
suggesting different and specific pathways of action. Recent
work has clearly shown that HDAC3 is part of a novel HDAC
pathway regulating mitosis by Aurora B kinase activity modu-
lation (38). The aim of this study was to define in detail the role
of HDAC1 in tumor cells and, in parallel, to provide molecular
insight into HDAC1 functions by conducting a global gene
expression study in the U2OS cell line. It is known that the
effects of HDAC inhibitors are cell line specific and can be
HDAC inhibitor selective (14), providing ground for detailed
studies of which HDAC is responsible for which phenotype in
the cell line of interest. It has also been demonstrated that the
expression profiles induced by HDAC inhibitors are cell line
dependent and that, since the expression patterns of HDACs
vary from cell line to cell line, we can anticipate different
effects upon knockout of any particular HDAC (4, 14). In
U2OS and MCF7 cells, the absence of HDAC1 had a remark-
able effect on both apoptosis and proliferation and this phe-
notype was exacerbated by the simultaneous lack of HDAC2.
Interestingly, MCF10A, the untransformed counterpart of the
MCF7 cells, was less sensitive to the lack of HDAC1. In fact,
the effects on both proliferation and cell cycle were not as
evident (Fig. 2 and 3). These results are in agreement with the
idea that HDAC inhibitors have antiproliferative and proapop-
totic properties mainly in transformed cells (4, 41). We also
identified caspase-3 as a mediator of the apoptosis provoked by
the absence of HDAC1. Caspase-3 is a proapoptotic enzyme
and triggers apoptosis through both the intrinsic and the death
ligand pathways (20, 21). It is therefore a very good apoptosis
indicator. However, the most striking effect we observed was
the lack of mitotic cells in the absence of HDAC1 (Fig. 3 and
4). This result implies that HDAC1 is essential for mitosis, a
yet-undescribed observation. As expected by published data
showing that HDAC6 is the major tubulin deacetylase and that
HDAC1 has no specific tubulin deacetylase activity (25, 57), we
did not observe changes in tubulin acetylation following
siRNA-mediated knockdown of HDAC1 to HDAC3 (data not
shown). All cells interfered against HDAC1 had a nuclear
appearance typical of interphase or apoptosis. Taken together,
these data suggest that human tumor cells lacking HDAC1
cannot enter mitosis and therefore undergo apoptosis through
caspase-3 activation. Future work will further characterize the
mechanism of mitotic arrest. Our data are, however, consistent
with studies pointing to the importance of histone deacetyla-
tion in the formation of pericentric heterochromatin (9, 50)
and showing that loss of a component of the Sin3/HDAC1/
HDAC2 complex leads to cell death due to missegregation of
chromosomes during mitosis (8). Interestingly, loss of HDAC1
in untransformed cells, such as ES cells, fibroblasts, and neu-
rons, does not induce apoptosis (37; G. Lagger, R. Grausen-
burger, and C. Seiser, unpublished data), perhaps because of a
possible checkpoint activation in these cells or compensation
by HDAC2.
Based on our microarray results, the analysis of global gene
expression profiles of U2OS cells in the absence of HDAC1,
HDAC2, HDAC3, or HDAC1 plus HDAC2 yielded a large
number of genes that present altered expression levels (see
the supplementary data posted at http://bio.ifom-ieo-campus.it
/supplementary/MCB49407/). HDAC1 and HDAC1 plus HDAC2
knockdown regulated a largely overlapping set of genes, in-
cluding most of those regulated by HDAC2 knockdown.
HDAC3 knockdown caused the deregulation of a vast number
of genes. Interestingly, 50% of genes induced by HDAC3
knockdown were also induced by ablation of HDAC1 or
HDAC1 plus HDAC2 expression, whereas only 21% of genes
repressed by HDAC3 knockdown were in common with the
other conditions. These results could be a consequence of the
protein reduction of HDAC1 and HDAC2 we observed after
HDAC3 knockdown (Fig. 1).
Again, we analyzed in greater detail the genes regulated by
HDAC1. In accordance with the proposed role of HDAC1 as
a transcriptional repressor, more HDAC1 target genes were
upregulated than downregulated in the absence of HDAC1.
Interestingly, this result evened out when both HDAC1 and
HDAC2 were ablated. This is in line with several reports that
have demonstrated the independent recruitment of HDAC1
and HDAC2 to target genes (26, 49).
Because of the phenotype observed in the absence of
HDAC1 (and HDAC1 plus HDAC2), we validated genes in-
volved in apoptosis and proliferation. Notably, a number of
cyclins, cyclin-dependent kinases, and the cyclin-dependent ki-
nase inhibitor p21, whose expression is tightly coordinated to
regulate appropriate cell cycle progression, were induced after
RNAi treatment against HDAC1. p21 has been regarded as an
attractive therapeutic target in human cancer. Although a
plethora of data regarding the role of this multifunctional
protein in many cellular pathways has emerged, the precise
mechanism by which p21 regulates cell cycle progression is still
unknown, partly because p21 can act in both a positive and a
negative fashion toward cell proliferation (53). Given that p21
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expression is increased upon HDAC1 knockdown in U2OS
cells but not in MCF7 cells, we would argue that the mitotic
phenotype observed in these two tumor cell lines is not linked
to p21. Our microarray data also showed repression of
CDC25C and septin 6. In Saccharomyces cerevisiae, the septins
are a family of cell division cycle regulatory proteins and have
been associated with actin stress fibers in interphase cells, the
cleavage furrow of dividing cells, and the bud neck of budding
yeast (reviewed in reference 31). The human homologue of
septin 6 has been found to be fused to MLL in a few cases of
infant acute myeloid leukemia (43). Cdc25C phosphatase is a
major cell cycle regulator in mammals. Its C-terminal catalytic
phosphatase domain dephosphorylates Cdc2 to promote G2/M
transition (27), whereas the N-terminal regulatory domain con-
tains multiple phosphorylation sites. Multisite phosphorylation
of Cdc25C by different kinases recruits specific proteins, con-
trolling the normal cellular mitotic progression (reviewed in
reference 56). Clearly, both Septin6 and Cdc25C have impor-
tant roles in mitosis. Finally, the activation of many interleu-
kins after HDAC ablation could be because of a postapoptotic
activation of an inflammation response.
In summary, we have defined a role for HDAC1 in the
proliferation of human tumor cells and, most importantly,
identified a mitotic defect in human tumoral cells after knock-
down of HDAC1. These results confirm once again the impor-
tance of characterizing the biological function of HDAC1,
also in light of its potential significance as a target for cancer
therapy.
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